TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3881309
Drug: Metoclopramide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (two 10-mg capsules t.i.d.)
Study: 488520
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules)
Study: 29678170
Drug: Suture repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suture repair group with dynamic augmentation and microfracture of the femoral notch
Study: 27055679
Drug: 3% diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diquafosol sodium ophthalmic solution (DQS)
Study: 22167565
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) dosing strategies
Study: 21425572
Drug: Xiongshao Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiongshao Capsule (XSC)
Study: 20124517
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg daily)
Study: 15470330
Drug: Rifabutin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (300 mg daily)
Study: 10223781
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral contraceptives only)
Study: 2083081
Drug: Dermoval cream
Normalized name: clobetasol propionate Topical Ointment [Dermovate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermoval cream
Study: 2083081
Drug: Colorimetric parameters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorimetric parameters a* (redness) and L* (luminance)
Study: 630211
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (combination and single-agent chemotherapy)
Study: 30929590
Drug: Art Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art Therapy (AT) for eight weeks
Study: 30929590
Drug: Sham Art
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham Art Therapy (mandala coloring group) for eight weeks
Study: 23351071
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) therapy
Study: 16504835
Drug: Demographic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographic and clinical variables (age, duration of diabetes, insulin use, smoking history, hypertension, BMI, race, ethnicity, cholesterol levels, statin use)
Study: 12946547
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg QD for 12 months
Study: 12946547
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg QD for 12 months
Study: 10989265
Drug: MDMA (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.7 mg/kg)
Study: 7994166
Drug: Incremental intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental intravenous infusion of adrenaline (low, intermediate, high doses)
Study: 2544291
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravenous GR43175
Study: 429499
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sulpiride orally twice a day during the first 7 days of the puerperium
Study: 429499
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sulpiride orally
Study: 29136343
Drug: MOD-4023 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD-4023 (7.5 mg)
Study: 29136343
Drug: MOD-4023 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD-4023 (all doses)
Study: 17488174
Drug: Orff-based music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orff-based music therapy
Study: 11920985
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) with exposure-based behavior therapy
Study: 11920985
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) with nonexposure-based behavior therapy
Study: 9760611
Drug: No capsule-bending
Approvals — FDA: no, EMA: no, PMDA: no
Description: No capsule-bending ring (Control)
Study: 6957155
Drug: Gemfibrozil (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (1200 mg daily)
Study: 30894208
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg q2w + MTX
Study: 30894208
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg q2w + MTX
Study: 25733246
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg
Study: 19428923
Drug: AMA1-C1 vaccine
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1-C1 vaccine with Alhydrogel
Study: 9590971
Drug: Diclofenac‐potassium 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac‐potassium 50 mg
Study: 9590971
Drug: Glafenine 200
Normalized name: Glafenine
DrugBank: Glafenine (DB08963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glafenine 200 mg
Study: 9512220
Drug: Dexamethasone administration
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administration
Study: 28717347
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil group (n=10) consuming eight 300-mg EPA-rich fish oil softgel capsules per day for 8 weeks and continued for 5 days after exercise.
Study: 28717347
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=11) consuming an equivalent number of placebo capsules.
Study: 9158644
Drug: Warfarin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (control group)
Study: 18318674
Drug: Antenatal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroid treatment (experimental group)
Study: 18318674
Drug: No antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antenatal corticosteroid treatment (control group)
Study: 16898074
Drug: Reference oral
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference oral solution (0.3 mg/100 ml)
Study: 1894861
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous diltiazem infusion (10 to 15 mg/h)
Study: 1894861
Drug: Combined diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined diltiazem infusion (double-blind and open label)
Study: 29171358
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) oxycodone (crushed)
Study: 17005043
Drug: Adalimumab (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (two doses, subcutaneously administered)
Study: 8025209
Drug: Preventive therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive therapies for insulin-dependent diabetes (specific therapies not detailed)
Study: 3344936
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Cladosporium herbarum
Study: 27660194
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus structured, tailored group physical exercise (S + EX)
Study: 22947426
Drug: Maribavir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maribavir (100 mg twice daily)
Study: 18207225
Drug: Methamphetamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (3 mg, IV)
Study: 21803113
Drug: Rivastigmine 3
Normalized name: rivastigmine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 3 mg
Study: 15998547
Drug: Decubitus direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decubitus direct current treatment (DDCT)
Study: 9431834
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg
Study: 4015285
Drug: Oxprenolol 160
Normalized name: oxprenolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 160 mg
Study: 1350485
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg
Study: 25103305
Drug: Erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib treatment
Study: 29968431
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/day)
Study: 1729588
Drug: Psychiatric consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychiatric consultation advising physicians on treatment
Study: 1729588
Drug: First-generation antidepressants
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antidepressants (amitriptyline, imipramine, doxepin)
Study: 1729588
Drug: Newer antidepressants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antidepressants (nortriptyline, desipramine, trazodone, fluoxetine)
Study: 6431572
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine, sublingually
Study: 6431572
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate by inhalation
Study: 28548626
Drug: Inactivated EV71
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated EV71 vaccine
Study: 27323615
Drug: Ligustrazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine (2 mg/kg)
Study: 20339154
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment with pravastatin (40 mg once daily)
Study: 20339154
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment without pravastatin
Study: 11329096
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg orally in the morning and placebo in the evening
Study: 27599329
Drug: Estriol 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol 0.1% (0.4 mg/d)
Study: 25058146
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (3.0 g/day of NaCl) for 7 days
Study: 25058146
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (18.0 g/day of NaCl) for 7 days
Study: 25058146
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet with potassium supplementation (18.0 g/day of NaCl + 4.5 g/day of KCl) for 7 days
Study: 22297625
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg IV plus ondansetron 4 mg IV (group DO)
Study: 22297625
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg IV (group D)
Study: 21175313
Drug: Imatinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (600 mg daily)
Study: 21175313
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 mg daily) plus cytarabine (20 mg/m² daily on days 15-28)
Study: 12488409
Drug: CVP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVP (cyclophosphamide 750 mg/m² and vincristine 1.2 mg/m² intravenously on day 1, prednisone 40 mg/m² orally on days 1 to 5, every 21 days)
Study: 8587758
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of 5% glucose water containing 4 g of regular instant coffee
Study: 8587758
Drug: Baseline: 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline: 500 ml of 5% glucose water
Study: 2632448
Drug: Topical sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sulindac therapy
Study: 26237828
Drug: WCR (insulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: WCR (insulin, isoniazid, rifampicin, pyrazinamide, ethambutol)
Study: 23483023
Drug: Ensure preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensure preparation
Study: 3310200
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg in the evening
Study: 16634072
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment with Er:YAG laser (12.7 J/cm2)
Study: 15292850
Drug: Rehabilitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation group (160 mg/d oral testosterone undecanoate for men, 80 mg/d for women, 563 kcal/d oral dietary supplements, exercise on ergometric bicycle 3 to 5 times a week)
Study: 29523206
Drug: School-based humanistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based humanistic counselling (SBHC) delivered in up to 10 weekly sessions by a qualified counsellor.
Study: 12665049
Drug: Two 80‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 80‐mg tablets twice daily
Study: 12665049
Drug: Two 80‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 80‐mg tablets three times daily
Study: 2654214
Drug: Twice-daily (nonoccluded)
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily (nonoccluded) superpotent topical steroids for 2 weeks
Study: 2669553
Drug: Topical glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticosteroids
Study: 962352
Drug: Matched control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched control group (no steroid treatment)
Study: 962352
Drug: Topical glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticosteroids (retesting after one month)
Study: 25445851
Drug: Intermediate voice
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate voice therapy (from 4 to 8 weeks after injury)
Study: 25445851
Drug: Delayed voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed voice therapy (at least 8 weeks after injury)
Study: 11323139
Drug: Sequential spatial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential spatial discrimination for touch
Study: 3127600
Drug: Keyhole-limpet hemocyanin
Normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keyhole-limpet hemocyanin (1 mg intracutaneously for immunization, followed by 10 mg monthly bladder instillations)
Study: 3127600
Drug: Keyhole-limpet hemocyanin
Normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keyhole-limpet hemocyanin (10 mg monthly bladder instillations)
Study: 3127600
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (20 mg monthly)
Study: 30651321
Drug: TTP399 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTP399 (800 mg/day)
Study: 15192923
Drug: Calculated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calculated insulin dose (CALC)
Study: 15192923
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin dose (C)
Study: 11275919
Drug: Long-acting antianginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting antianginal medications (long-acting diltiazem +/− nitroglycerin patches +/− atenolol)
Study: 11275919
Drug: Optimal adjustment
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal adjustment of usual antianginal medications
Study: 2839321
Drug: Psyllium 3.4
Normalized name: psyllium 3.4 g oral wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium 3.4 g
Study: 27166077
Drug: Psyllium 10.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium 10.2 g
Study: 27166077
Drug: Psyllium 6.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium 6.8 g (Study 2)
Study: 23895084
Drug: Trauma‐focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma‐focused cognitive behavioral therapy (TF‐CBT)
Study: 23895084
Drug: Therapy as
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy as usual (TAU)
Study: 20557327
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) administered subcutaneously every 2 weeks, titrated to maintain a target Hb level of 14.0±1.0 g/dL
Study: 15877291
Drug: 1.2 g/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g/min of glucose + 1.2 g/min of sucrose (H-GLU+SUC)
Study: 12552030
Drug: Topiramate 500
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 500 mg/d
Study: 18215213
Drug: Topiramate 200
Normalized name: topiramate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 200 mg/d
Study: 15096395
Drug: Topiramate 50
Normalized name: topiramate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 50 mg/d
Study: 9802630
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G diluted with lidocaine hydrochloride 1%
Study: 23555624
Drug: internet-delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered Cognitive Behaviour Therapy (iCBT)
Study: 19367435
Drug: 0.25% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% glyceryl trinitrate ointment and anal cryothermal dilators
Study: 19367435
Drug: 0.4% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% glyceryl trinitrate ointment alone
Study: 16957424
Drug: Telmisartan-HCTZ (80/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan-HCTZ (80/25 mg)
Study: 16957424
Drug: Valsartan-HCTZ (160/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan-HCTZ (160/25 mg)
Study: 1624025
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 3.75 mg
Study: 24738111
Drug: Conventional antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotics (perphenazine, sulpiride, chlorpromazine)
Study: 10546391
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (IPIC) lasting four days
Study: 8756737
Drug: Hemodialysis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis therapy for over 50 months
Study: 6869735
Drug: Thiopentone 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 4.5 mg/kg
Study: 25048383
Drug: Albiglutide (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide (once-weekly subcutaneous)
Study: 25048383
Drug: Sitagliptin (daily)
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin (daily)
Study: 17898654
Drug: Liposomal daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal daunorubicin (DaunoXome) 50 mg/m
Study: 12488411
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cyclophosphamide, epirubicin, and vincristine (CEV)
Study: 9296416
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine
Study: 30559966
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT)
Study: 2653757
Drug: Two different
Normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two different diabetes treatment regimens
Study: 17132650
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (no adenosine pretreatment)
Study: 7767194
Drug: Hyperbaric chamber
Normalized name: HOLDING CHAMBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric chamber treatment at 193 mbar for 1 hour
Study: 2312782
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate 200 mg orally every 8 hours for 24 hours prior to antipyrine administration
Study: 2312782
Drug: Antipyrine 1
Normalized name: antipyrine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine 1 gram dose alone
Study: 6774845
Drug: 4580 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4580 rad in 10 treatments, 11 days overall
Study: 16278522
Drug: Thiazide-type diuretics
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide-type diuretics
Study: 31628783
Drug: ABP 710
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABP 710 (5 mg/kg intravenously over 2 hours)
Study: 31628783
Drug: Infliximab US
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab US (5 mg/kg intravenously over 2 hours)
Study: 31628783
Drug: Infliximab EU
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab EU (5 mg/kg intravenously over 2 hours)
Study: 29390538
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy (35 to 45 minutes, 2 times/week for 12 weeks)
Study: 29390538
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy only
Study: 20496741
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with bloodletting therapy
Study: 20496741
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with western medicine (e.g., catgut embedding therapy with Fluoxetine, electroacupuncture with Seroxat)